American Association of Clinical Endocrinology Annual Meeting

American Association of Clinical Endocrinology Annual Meeting

May 06, 2017
2 min watch

VIDEO: Treatment options expanding for postmenopausal osteoporosis

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

AUSTIN, Texas—In this video exclusive, John P. Bilezikian, MD, the Dorothy L. and Daniel H. Silberberg Professor of Medicine and professor of pharmacology at the College of Physicians and Surgeons at Columbia University and chief of the division of endocrinology and director of the metabolic bone diseases program at Columbia University Medical Center, describes how the recent approval of abaloparatide will change how he treats patients.

Abaloparatide (Tymlos, Radius Health) is the first anabolic agent approved for treatment of postmenopausal osteoporosis in nearly 15 years.

“In a field where the disease is characterized by bone being broken down, the opportunity to build up bone with a drug like Tymlos is very exciting,” Bilezikian said. “It gives me as a physician and also me as an academic investigator an opportunity to learn more about the field of osteoporosis, but more importantly it gives me an opportunity to treat patients, giving us an opportunity to treat postmenopausal women who are at high risk for fracture.”